Abbvie Inc. vs Pfizer Inc.
ABBV vs PFE — side-by-side comparison from reported financials. ABBV leads 8, PFE leads 3 of 11 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Pfizer Inc.
PFE · Healthcare
$28.27+1.62%Mixed
| Metric | ABBV | PFE |
|---|---|---|
| Price | $276.43 | $28.27 |
| Market cap | $488B | $161B |
| Revenue (TTM) | $64.4B | $63.7B |
| Revenue growth | +1.8% | -14.8% |
| Net margin | 9.8% | 6.8% |
| Free cash flow | $18.2B | $11.0B |
| Net cash (debt) | ($56.2B) | ($51.6B) |
| 1-year price return | +19.8% | +12.0% |
| P/E | 77.4 | 37.2 |
| P/E vs own history (cheap-side %) | 23% | 4% |
| Dividend yield | 2.45% | 6.07% |
| Return on equity | 96% | 5% |
| Altman Z-score | 2.33 | 1.96 |
| CV checks passed | 9 of 11 | 9 of 11 |
| Employees | 57,000 | 75,000 |
Full résumé-style profiles: ABBV CV · PFE CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.